Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of Antibody

a technology of specific binding molecules and antibodies, applied in the direction of antibody medical ingredients, drug compositions, peptides, etc., can solve the problems of limiting the use of these drugs, and 30% of patients are refractory to pharmacotherapy

Inactive Publication Date: 2021-03-18
MEDANNEX LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a method for modifying the structure of a polypeptide, such as a protein, by deleting or inserting amino acids. This can help to reduce the size and weight of the polypeptide without affecting its function. This can be useful for reducing the amount of polypeptide required for a particular application. Additionally, if side effects develop, the dosage can be reduced accordingly. Overall, this method allows for more efficient and targeted modification of polypeptides.

Problems solved by technology

Yet, around 30% of the patients are refractory to pharmaco- and behavioural therapy.
In addition, side effects such as agranulocytosis (loss of the white blood cells that help a person fight infection) and changes in a person's metabolism (leading to diabetes) are serious problems that limit the use of these drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Antibody
  • Use of Antibody
  • Use of Antibody

Examples

Experimental program
Comparison scheme
Effect test

example 1

N OF ANTIBODY VJ-4B6

[0102]A novel anti-AnxA1 antibody was generated by genetic immunisation as indicated in the scheme in FIG. 3A (Genovac GmbH, Germany). Serum from several immunized mice were tested and three resulted positive for IgG recognizing cells transfected with AnxA1 cDNA. Splenocytes from these mice were fused to myeloma cells to generate hybridoma cells. Only one of the three hybridoma cell clones were successfully subcloned and expanded. These hybridoma cells are called VJ-4B6-E5-B10-D4. Purified IgG2b fraction from the hybridoma cells recognizes cells transfected with AnxA1 cDNA (FIG. 3B, green line; right-hand peak) but not cell transfected with an irrelevant cDNA (FIG. 3B, red line; left-hand peak).

example 2

G OF VJ-4B6

[0103]The aim of this Example was to clone the antibody heavy and light chain variable region genes from the hybridoma cells and to determine the DNA sequence and location of the complementarity determining regions (CDRs) and other features.

[0104]Cloning and Sequencing of Antibody Variable Regions

[0105]Total RNA was prepared from 1 vial of hybridoma cells using the Qiagen RNeasy mini kit (Cat No: 74104). RNA was eluted in 50 μL water and checked on a 1.2% agarose gel.

[0106]VH and VK (variable kappa light chain) cDNAs were prepared using reverse transcriptase with IgG and kappa constant region primers. The first strand cDNAs were amplified by PCR using a large set of signal sequence primers. The amplified DNAs were gel-purified and cloned into the vector pGem® T Easy (Promega). The VH and VK clones obtained were screened for inserts of the expected size. The DNA sequence of selected clones was determined in both directions by automated DNA sequencing. The locations of the ...

example 3

F VJ-4B6 ON MOUSE MODEL OF OBSESSIVE COMPULSIVE DISORDER (OCD) IN VIVO

[0114]The present inventors have developed a transgenic mouse model of obsessive compulsive disorder in which Anx-A1 is overexpressed in T cells. This is the subject of co-pending UK patent application no. 1121561.3 which was filed on the same day as the present application.

[0115]Transgenic mice overexpressing Anx-A1 (Anx-A1tg) in T cells were generated by inserting C-terminus FLAG-tagged Anx-A1 into the mouse genome using a VACD2 cassette vector and the technique of pronuclear microinjection. Briefly, the murine Anx-A1 gene was amplified and tagged with the FLAG epitope and then cloned into the pcDNA3.1 vector. The Anx-A1 FLAG was recovered from the pcDNA3.1 vector and then ligated into linearised VACD2 vector. The VACD2 Anx-A1 FLAG construct was then modified and purified, then inserted into the mouse genome by pronuclear injection. These mice were used in the present Example as follows.

[0116]Mice received an in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a specific binding molecule that binds to Annexin-1 (Anx-A1) for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD. The invention also provides a pharmaceutical composition comprising a specific binding molecule of the invention for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD.

Description

FIELD OF THE INVENTION[0001]The present invention relates to the use of specific binding molecules, particularly antibodies and fragments thereof, which bind to annexin-A1, in the treatment of obsessive-compulsive disorder (OCD) and related diseases.BACKGROUND TO THE INVENTION[0002]Obsessive compulsive disorder (OCD) is a chronic, relapsing psychiatric affliction with a lifetime prevalence of 1-3%. According to the Diagnostic and Statistical Manual of Mental Disorders (4th ed; DSM IV), the essential features of this disease are recurrent obsessions and / or compulsions (e.g., doubting, checking, washing) that are time consuming (i.e., they take more than 1 hour a day) or cause marked distress or significant impairment.[0003]The most effective treatments for mental disorders like OCD are antipsychotic and behavioural treatments. Yet, around 30% of the patients are refractory to pharmaco- and behavioural therapy. In addition, side effects such as agranulocytosis (loss of the white blood...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/18A61K39/395
CPCC07K16/18A61K2039/505A61K39/3955A61P25/00A61P25/18A61P25/22A61P25/24C07K2317/14C07K2317/24C07K2317/565C07K2317/569
Inventor D'ACQUISTO, FULVIOPERRETTI, MAURO
Owner MEDANNEX LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com